Optotree

OptoTree is a private, pre-revenue diagnostics company leveraging its proprietary Vasculomics® platform to analyze 3D micro-vascular geometry from OCT-A scans for the early detection and staging of diabetic retinopathy. Formed as a collaboration between Joslin Diabetes Center and Vasculomics Holdings Group, the company aims to commercialize a cloud-based diagnostic service for clinics and eventually provide data informatics. Its technology, originally used in oncology drug discovery, is being repurposed to address a critical need in diabetic eye care, with a significant market opportunity driven by the global diabetes epidemic.

Vasculomics® medical vascular analytical technology/software platform. A patented platform that analyzes 3D micro-vascular geometry/morphology patterns from tomographic scans (like OCT-A) to detect and quantify disease. Originally used in oncology drug discovery, now being adapted for diabetic retinopathy diagnosis.

Competition is intense in the AI retinal diagnostics space, with many companies (e.g., IDx-DR, Eyenuk, Google Health) already FDA-cleared for autonomous DR detection from 2D fundus photographs. OptoTree's differentiation is its focus on 3D micro-vascular analysis from OCT-A scans, which could provide earlier and more detailed staging, but it competes against a more established and potentially lower-cost 2D imaging standard.